

# Genome-wide Association Study


02/11/2019

Qi Yan


Department of Pediatrics

Children's Hospital of Pittsburgh of UPMC

University of Pittsburgh



# Human Genome and Single Nucleotide Polymorphisms (SNPs)




- 23 chromosome pairs
- 3 billion bases
- A single nucleotide change between pairs of chromosomes
- E.g.

**Haplotype1:** AAGGGATCCAC


**Haplotype2:** AAGGAATCCAC

# Where are Genes?



■ Marker allele A1 cosegregates with disease

# Association Study in Population




# What are Genes?

- Identify genetic variants that are associated with disease...
- E.g. Mutations which disrupt NOD2 are much more common in Crohn's patients

	Crohn's	Controls
● Arg702Trp:	11%	4%
● Gly908Arg:	4%	2%
● Leu1007fs	8%	4%


# Using SNPs to Track Predisposition to Disease



# SNP Data

## SNP genotyping via direct hybridization


- SNP1 with alleles T/G
- SNP2 with alleles A/G



[www.cd-genomics.com](http://www.cd-genomics.com)

	SNP1	SNP2	SNP3	...
Sample1	A/A	G/G	G/G	...
Sample2	A/A	A/G	G/G	...
Sample3	A/C	G/G	G/G	...
...	...	...	...	...

## SNP Calling from Genomic DNA Reads



BIBM 2011 Tutorial

OR

	SNP1	SNP2	SNP3	...
Sample1	0	2	2	...
Sample2	0	1	2	...
Sample3	1	2	2	...
...	...	...	...	...

# SNPs in Population





# Association Study in Case Control Samples

SNP1	SNP2	SNP3	SNP4	SNP5	Disease
↓	↓	↓	↓	↓	
C <b>A</b> GATCGCTGG <b>A</b> TG <b>A</b> ATC <b>G</b> CATC	C <b>G</b> GATTGCTGG <b>C</b> ATG <b>G</b> ATC <b>G</b> CATC	C <b>A</b> GATCGCTGG <b>A</b> TG <b>A</b> ATC <b>G</b> CATC	C <b>A</b> GATCGCTGG <b>A</b> TG <b>A</b> ATC <b>G</b> CATC	C <b>A</b> GATCGCTGG <b>A</b> TG <b>A</b> ATC <b>G</b> CATC	
C <b>G</b> GATTGCTGG <b>C</b> ATG <b>G</b> ATC <b>C</b> CATC	C <b>G</b> GATTGCTGG <b>C</b> ATG <b>G</b> ATC <b>C</b> CATC	C <b>G</b> GATTGCTGG <b>C</b> ATG <b>G</b> ATC <b>C</b> CATC	C <b>G</b> GATTGCTGG <b>C</b> ATG <b>G</b> ATC <b>C</b> CATC	C <b>G</b> GATTGCTGG <b>C</b> ATG <b>G</b> ATC <b>C</b> CATC	

# Association Studies and Linkage Disequilibrium

- If all polymorphisms were independent at the population level, association studies would have to examine every one of them...
- Linkage disequilibrium makes tightly linked variants strongly correlated producing cost savings for association studies

# Linkage Disequilibrium (LD)

		<u>Locus B</u>		Totals	
		<i>B</i>	<i>b</i>		
<u>Locus A</u>	<i>A</i>	$p_{AB}$	$p_{Ab}$	$p_A$	$p_{AB} = p_A p_B$
	<i>a</i>	$p_{aB}$	$p_{ab}$	$p_a$	$p_{Ab} = p_A p_b = p_A(1 - p_B)$
Totals		$p_B$	$p_b$	1.0	$p_{aB} = p_a p_B = (1 - p_A) p_B$
					$p_{ab} = p_a p_b = (1 - p_A)(1 - p_B)$

$$D_{AB} = p_{AB} - p_A p_B$$

$$p_{AB} = p_A p_B + D_{AB}$$

$$p_{Ab} = p_A p_b - D_{AB}$$

$$p_{aB} = p_a p_B - D_{AB}$$

$$p_{ab} = p_a p_b + D_{AB}$$




$$D_{AB} = p_{AB} p_{ab} - p_{Ab} p_{aB}$$

$$\Delta^2 = \frac{D_{AB}^2}{p_A(1 - p_A)p_B(1 - p_B)}$$

- Ranges between 0 and 1
  - 1 when the two markers provide identical information
  - 0 when they are in perfect equilibrium


# LD in Population




LD extends further in CEPH and the Han/Japanese than in the Yoruba

International HapMap Consortium, *Nature*, 2005

# Genetic Spectrum of Complex Diseases




# Genetic Spectrum of Complex Diseases



# Genome-Wide Association Study




# Progress in Genotyping Technologies






# Publications



# Published Genome-Wide Associations through 12/2013

## Published GWA at $p \leq 5 \times 10^{-8}$ for 17 trait categories




NHGRI GWA Catalog

[www.genome.gov/GWAStudies](http://www.genome.gov/GWAStudies)

[www.ebi.ac.uk/fgpt/gwas/](http://www.ebi.ac.uk/fgpt/gwas/)

# Clinical translation of findings from GWAS



# Allelic Test for Association

	<b>GG</b>	<b>GT</b>	<b>TT</b>	<b>Total</b>
<b>Cases</b>	$r_0$	$r_1$	$r_2$	$R$
<b>Controls</b>	$s_0$	$s_1$	$s_2$	$S$
<b>Total</b>	$n_0$	$n_1$	$n_2$	$N$

Observed allele counts

	<b>G</b>	<b>T</b>	<b>Total</b>
<b>Cases</b>	$2r_0+r_1$	$r_1+2r_2$	$2R$
<b>Controls</b>	$2s_0+s_1$	$s_1+2s_2$	$2S$
<b>Total</b>	$2n_0+n_1$	$n_1+2n_2$	$2N$

Expected allele counts

	<b>G</b>	<b>T</b>
	$2R(2n_0+n_1)/(2N)$	$2R(n_1+2n_2)/(2N)$
	$2S(2n_0+n_1)/(2N)$	$2S(n_1+2n_2)/(2N)$

Chi-square test for independence of rows and columns (null hypothesis):

$$\sum \frac{(\text{Obs} - \text{Exp})^2}{\text{Exp}} \sim \chi^2 \text{ with 1 df}$$

# Odds Ratio

Odds of an event occurring =  $\text{Pr}(\text{event occurs}) / \text{Pr}(\text{event doesn't occur})$   
=  $\text{Pr}(\text{event occurs}) / [1 - \text{Pr}(\text{event occurs})]$

	Allele counts	
	<b>G</b>	<b>T</b>
<b>Cases</b>	<i>a</i>	<i>b</i>
<b>Controls</b>	<i>c</i>	<i>d</i>

Consider all the G alleles in the sample, and pick one at random.  
The odds that the G allele occurs in a case:  $a/c$

Consider all the T alleles in the sample, and pick one at random.  
The odds that a T allele occurs in a case:  $b/d$

*odds ratio* =  $\frac{\text{odds that G allele occurs in a case}}{\text{odds that T allele occurs in a case}} = \frac{a/c}{b/d} = \frac{a d}{b c}$

# Logistic regression

- Let  $Y_i$  be the phenotype for individual  $i$   
 $Y_i = 0$  for controls  
 $Y_i = 1$  for cases
- Let  $X_i$  be the genotype of individual  $i$  at a particular SNP  
TT       $X_i = 0$   
GT       $X_i = 1$   
GG       $X_i = 2$
- Basic logistic regression model  
Let  $p_i = E(Y_i | X_i)$ , expected value of pheno given geno  
Define  $\text{logit}(p_i) = \log_e[p_i / (1 - p_i)]$

$$\text{logit}(p_i) \sim \beta_0 + \beta_1 X_i$$


Analogously, linear regression for continuous phenotype:

$$Y_i = \beta_0 + \beta_1 X_i$$

# Genotype Imputation

- Use genotypes at a few markers to infer genotypes at other unobserved markers
- Closely related individuals
  - Long segments of identify by descent
- Distantly related individuals
  - Shorter segments of identify by descent

# Genotype Imputation for unrelated Individuals





# Identify Match Among Reference

## Observed Genotypes

. . . . . **A** . . . . . **A** . . . . . **A** . . . .  
. . . . . **G** . . . . . **C** . . . . . **A** . . . .

## Reference Haplotypes

C G A G A T C T C C T T C T T C T G T G C  
**C G A G A T C T C C C G A C C T C A T G G**  
C C A A G C T C T T T T C T T C T G T G C  
C G A A G C T C T T T T C T T C T G T G C  
C G A G A C T C T C C G A C C T T A T G C  
T G G G A T C T C C C G A C C **T C A T G G**  
C G A G A T C T C C C G A C C T T G T G C  
C G A G A C T C T T T T C T T T T G T A C  
C G A G A C T C T C C G A C C T C G T G C  
**C G A A G C T C T T T T C T T** C T G T G C

# Impute Missing Genotypes and Phase Chromosome

## Observed Genotypes

c	g	a	g	A	t	c	t	c	c	c	g	A	c	c	t	c	A	t	g	g
c	g	a	a	G	c	t	c	t	t	t	t	C	t	t	t	c	A	t	g	g

## Reference Haplotypes

C	G	A	G	A	T	C	T	C	C	T	T	C	T	T	C	T	G	T	G	C
C	G	A	G	A	T	C	T	C	C	C	G	A	C	C	T	C	A	T	G	G
C	C	A	A	G	C	T	C	T	T	T	T	C	T	T	C	T	G	T	G	C
C	G	A	A	G	C	T	C	T	T	T	T	C	T	T	C	T	G	T	G	C
C	G	A	G	A	C	T	C	T	C	C	G	A	C	C	T	T	A	T	G	C
T	G	G	G	A	T	C	T	C	C	C	G	A	C	C	T	C	A	T	G	G
C	G	A	G	A	T	C	T	C	C	C	G	A	C	C	T	T	G	T	G	C
C	G	A	G	A	C	T	C	T	T	T	T	C	T	T	T	T	G	T	A	C
C	G	A	G	A	C	T	C	T	C	C	G	A	C	C	T	C	G	T	G	C
C	G	A	A	G	C	T	C	T	T	T	T	C	T	T	C	T	G	T	G	C


# Implementation

- Markov model is used to model each haplotype, conditional on all others
- At each position, we assume the haplotype being modeled copies as a template haplotype
- Each individual has two haplotypes, and therefore copies two template haplotypes



# Does This Really Work?

- Used about ~300,000 SNPs from Illumina HumanHap300 to impute 2.1M HapMap SNPs in 2500 individuals from a study of type II diabetes
- Compared imputed genotypes with actual experimental genotypes in a candidate region on chromosome 14
  - 1190 individuals, 521 markers not on Illumina chip
- Results of comparison
  - Average  $r^2$  with true genotypes 0.92 (median 0.97)
  - 1.4% of imputed alleles mismatch original
  - 2.8% of imputed genotypes mismatch
  - Most errors concentrated on worst 3% of SNPs

# GWAS Workflow



# Hypothetical Quantile-Quantile Plots in Genome-wide Association Studies



# A Successful Example

## Age Related Macular Degeneration (AMD)

- Progressive neurodegenerative disorder which leads to a loss of vision through the death of photoreceptors and/or retinal pigment epithelium (RPE) in the macula
- Late stage of the disease is associated with a debilitating loss of central vision and/or blindness

Images from National Eye Institute (<http://www.nei.nih.gov>)




Normal Vision



Advanced AMD impairment

# First GWAS of Age-related Macular Degeneration (AMD)

96 cases and 50 controls , 100K SNPs




Klein et al, *Science* 2005; 308:385-389.



# Later GWAS of AMD


2150 cases and 1157 controls , 370K SNPs



Chen et al, *PNAS* 2010

# Largest Meta-analysis of AMD


> 17,000 cases, > 60,000 controls, 2 M imputed HapMap SNPs



The AMD Gene Consortium, *Nat Genet* 2013

# Latest Meta-analysis of AMD


16,144 cases, 17,832 controls, 12 M imputed HapMap SNPs



the International AMD Genomics Consortium (IAMDG), *Nat Genet* 2016


# GWAS of AMD Progression

2,721 subjects, 9 M imputed 1000G phase3 SNPs



Yan et al, *Human Molecular Genetics* 2017

# Regional Plots



# GWA Study Design



- Sample Collection
  - Genotyping of single nucleotide polymorphisms (SNPs) was performed using a variety of platforms
  - Array densities ranged from roughly 200k to 1M SNPs/chip
  - Most samples were population based case-control studies, though some data came from family based (sib-pair) studies
- Quality Control (**PLINK**)
  - Samples screened unknown for population stratification
  - Rare SNPs (MAF < 1%-5%) and SNPs with high missing rate were excluded from the analysis
  - Hardy Weinberg Equilibrium for genotype frequency
  - Potential familial samples

# GWA Study Design



- Imputation
  - Each group participating in the discovery analysis calculated the allelic dosages using **IMPUTE2**
  - All imputation was performed using the **1000 Genome Project phase 3** reference panels
- Quality Control (**PLINK**)
  - SNPs of low imputation quality and/or extreme effect size which tend to indicate spurious associations were removed
  - After imputation and quality control measures, most data sets contain dosages for over 2 million SNPs per sample

# GWA Study Design



- Statistical Methods
  - A logistic regression model, or equivalent analysis, was used to test for association between allelic frequency and AMD risk
  - Contributing studies adjusted for population substructure as needed
  - The primary analysis model was unadjusted for age, though subsequent analysis did included age as a covariate
  - Primary model compared allelic frequencies between all advanced stages of AMD (neovascular AMD and GA) vs controls
  - **PLINK** for logistic and linear regression



# GWA Study Design



- Meta-analysis details
  - Meta-analysis of all the discovery GWAS was performed via **METAL** using the inverse fixed affects model
  - Total number of samples in the discovery analysis was approximately 7,600 cases and 50,000 controls
- Discovery Results
  - From this analysis, 32 loci show promising evidence for association an were further considered for the subsequent stage of replication analysis

# GWA Study Design



- Follow-up Analysis
  - 32 candidate SNPs from discovery analysis were sent for genotyping in an additional set of non-overlapping case-control samples ( $N_{\text{case}} > 9,500$ ;  $N_{\text{control}} > 8,200$ )
- Replication Results
  - After meta-analyzing these results with our discovery data, 19 loci attain genome-wide significance ( $p\text{-values} < 5.0 \times 10^{-8}$ )
  - Final tally of samples analyzed for SNPs in the replication data set comes to over 17,000 cases and over 60,000 controls

# 12 Loci previously observed to have genome-wide association with AMD risk

SNP/ Risk Allele	Chr	Pos(Mb)	Nearby Genes	EAF	Discovery		Follow-up		Meta	
					<i>P</i>	OR	<i>P</i>	OR	<i>P</i>	OR
rs10490924/T	10	124.2	<i>ARMS2</i>	0.3	$4 \times 10^{-353}$	2.7	$2.8 \times 10^{-190}$	2.9	$4 \times 10^{-540}$	2.8
rs10737680/A	1	195.0	<i>CFH</i>	0.64	$1 \times 10^{-283}$	2.4	$2.7 \times 10^{-152}$	2.5	$1 \times 10^{-434}$	2.4
rs429608/G	6	32.0	<i>C2/CFB</i>	0.86	$2 \times 10^{-54}$	1.6	$2.4 \times 10^{-37}$	1.9	$4 \times 10^{-89}$	1.7
rs2230199/C	19	6.7	<i>C3</i>	0.2	$2 \times 10^{-26}$	1.4	$3.4 \times 10^{-17}$	1.4	$1 \times 10^{-41}$	1.4
rs5749482/G	22	31.4	<i>SYN3/TIMP3</i>	0.74	$6 \times 10^{-13}$	1.3	$9.7 \times 10^{-17}$	1.4	$2 \times 10^{-26}$	1.3
rs4420638/A	19	50.1	<i>APOE</i>	0.83	$3 \times 10^{-15}$	1.3	$4.2 \times 10^{-7}$	1.3	$2 \times 10^{-20}$	1.3
rs1864163/G	16	55.6	<i>CETP</i>	0.76	$8 \times 10^{-13}$	1.2	$8.7 \times 10^{-5}$	1.2	$7 \times 10^{-16}$	1.2
rs943080/T	6	43.9	<i>VEGFA</i>	0.51	$4 \times 10^{-12}$	1.2	$1.6 \times 10^{-5}$	1.1	$9 \times 10^{-16}$	1.2
rs13278062/T	8	23.1	<i>TNFRSF10A</i>	0.48	$7 \times 10^{-10}$	1.2	$6.4 \times 10^{-7}$	1.1	$3 \times 10^{-15}$	1.2
rs920915/C	15	56.5	<i>LIPC</i>	0.48	$2 \times 10^{-9}$	1.1	0.004	1.1	$3 \times 10^{-11}$	1.1
rs4698775/G	4	110.8	<i>CFI</i>	0.31	$2 \times 10^{-10}$	1.2	0.025	1.1	$7 \times 10^{-11}$	1.1
rs3812111/T	6	116.6	<i>FRK/COL10A1</i>	0.64	$7 \times 10^{-8}$	1.1	0.022	1.1	$2 \times 10^{-8}$	1.1

# 7 loci showing genome-wide significant association with AMD risk for the first time

SNP/Risk Allele	Chr	Pos	Nearby Genes	EAF	Discovery		Follow-up		Meta	
					<i>P</i>	OR	<i>P</i>	OR	<i>P</i>	OR
rs13081855/T	3	101.0 Mb	<i>COL8A1</i>	0.1	$4 \times 10^{-11}$	1.3	$6.0 \times 10^{-4}$	1.2	$4 \times 10^{-13}$	1.2
rs3130783/A	6	30.9 Mb	<i>IER3/DDR1</i>	0.79	$1 \times 10^{-6}$	1.2	$3.5 \times 10^{-6}$	1.2	$2 \times 10^{-11}$	1.2
rs8135665/T	22	36.8 Mb	<i>SLC16A8</i>	0.21	$8 \times 10^{-8}$	1.2	$5.6 \times 10^{-5}$	1.1	$2 \times 10^{-11}$	1.2
rs334353/T	9	100.9 Mb	<i>COL15A1/TGFBR1</i>	0.73	$9 \times 10^{-7}$	1.1	$6.7 \times 10^{-6}$	1.1	$3 \times 10^{-11}$	1.1
rs8017304/A	14	67.9 Mb	<i>RAD51B</i>	0.61	$9 \times 10^{-7}$	1.1	$2.1 \times 10^{-5}$	1.1	$9 \times 10^{-11}$	1.1
rs6795735/T	3	64.7 Mb	<i>ADAMTS9</i>	0.46	$9 \times 10^{-8}$	1.1	0.0066	1.1	$5 \times 10^{-9}$	1.1
rs9542236/C	13	30.7 Mb	<i>B3GALTL</i>	0.44	$2 \times 10^{-6}$	1.1	0.0018	1.1	$2 \times 10^{-8}$	1.1

# Functional Analysis

- Gene set enrichment of all implicated results was run using Ingenuity Pathway Analysis (IPA) software.

**Table 3 Pathway analysis**

Ingenuity canonical pathways	Enrichment analysis			
	Nominal <i>P</i> value	FDR <i>q</i> value	Molecules	Pathway size ( <i>N</i> <sub>genes</sub> )
Complement system	0.000012	0.0015	<i>CFI, CFH, C3, CFB<sup>a</sup>, C2<sup>a</sup>, C4A<sup>a</sup>, C4B<sup>a</sup></i>	35
Atherosclerosis signaling	0.00014	0.009	<i>PLA2G12A, APOC1<sup>b</sup>, APOE<sup>b</sup>, APOC2<sup>b</sup>, APOC4<sup>b</sup>, TNFSF14, COL10A1, PLA2G6</i>	129
VEGF family ligand-receptor interactions	0.0042	0.150	<i>VEGFA, PLA2G12A, PLA2G6</i>	84
Dendritic cell maturation	0.0046	0.150	<i>RELB, ZBTB12, DDR1, COL10A1</i>	185
Phospholipid degradation	0.0058	0.151	<i>PLA2G12A, LIPC, PLA2G6</i>	102
MIF-mediated glucocorticoid regulation	0.0088	0.153	<i>PLA2G12A, PLA2G6</i>	42
Inhibition of angiogenesis by TSP1	0.0093	0.153	<i>VEGFA, TGFBR1</i>	39
FceRI signaling	0.0098	0.153	<i>VAV1, PLA2G12A, PLA2G6</i>	111
p38 MAPK signaling	0.011	0.153	<i>PLA2G12A, TGFBR1, PLA2G6</i>	106

FDR, false discovery rate.

<sup>a</sup>All flank rs429608 and are thus counted as a single hit when determining the significance of enrichment. <sup>b</sup>All flank rs4420638 and are thus counted as a single hit when determining the significance of enrichment.

# Summary

- GWAS have been successful in identifying genetic variants associated with common diseases and traits.
- A large proportion of heritability remains unexplained by GWAS and very limited functional knowledge is known at most identified loci.
- Next generation sequencing will be the next step to dissect the genetic basis beyond GWAS.

# References

- <http://www.genome.gov/gwastudies/>
- <http://pngu.mgh.harvard.edu/~purcell/plink/>
- Mark I. McCarthy et al. Genome-wide association studies for complex traits: consensus, uncertainty and challenges. Nature Review Genetics. 2008
- The AMD Gene Consortium. Seven New Loci Associated with Age-Related Macular Degeneration. Nature Genetics. 2013
- The International AMD Genomics Consortium (IAMDGCC). A large genome-wide association study of age-related macular degeneration highlights contributions of rare and common variants. Nature Genetics. 2016